OUR TECHNOLOGY · POROUS-WALL HOLLOW GLASS MICROSPHERES

A small sphere.
A new way to think about drug delivery.

SpheroFill is developing a versatile pharmaceutical delivery platform built around tiny hollow glass microspheres. Their distinctive architecture creates opportunities to engineer how therapeutic compounds are loaded, protected, and released.

ONE PLATFORM. MULTIPLE ENGINEERING POSSIBILITIES.
THE PLATFORM

Five ways to explore the platform

One distinctive hollow-reservoir architecture. Multiple ways to investigate pharmaceutical loading, release, and interactions with the biological environment. Explore the platform from the inside out.

FEATURED DEVELOPMENT FOCUS

Rethinking the challenges of oral drug delivery.

Oral medicines must navigate a complex biological environment. For some therapies, limited solubility, degradation, premature release, or the need for delivery at a specific intestinal site can complicate formulation.

SpheroFill is exploring how a spacious hollow reservoir, porous shell, and engineered surface might offer complementary approaches to these challenges within a single platform.

What we've shown—and what's next ↓
Poorly soluble compounds

Exploring formulation approaches that may help address the challenges posed by poorly soluble pharmaceutical compounds.

Protection and release

Exploring barriers and pore-gating strategies to influence exposure to changing gastrointestinal conditions.

Localized intestinal delivery

Researching surface interactions and residence characteristics that may support site-focused delivery strategies.

Emerging therapeutic modalities

Investigating delivery concepts involving sensitive biological cargo, including RNA and peptide-based therapeutics.

SCIENCE WITH CLARITY

What we've observed. What we're investigating.

A promising architecture is a starting point, not proof of therapeutic performance. Our research program includes demonstrated microsphere structure and pharmaceutical loading, ongoing work to evaluate release behavior and potential oral delivery applications.

We aim to distinguish experimental observations from proposed mechanisms, and to test formulation-specific performance with appropriate analytical methods.

A platform built for inquiry

Established platform features: Hollow silica-rich microspheres with interconnected porous walls; demonstrated research-scale loading of different cargo classes.

Active research programs: Additional formulation-engineering capabilities are being investigated, with selected technical disclosures withheld during intellectual-property review.

Active research questions: Whether coatings and release characteristics can improve oral drug performance, site selectivity, or stability in particular formulations.

GO DEEPER

Explore the science with SpheroFill Insights

A growing educational series examining the underlying science, promising research directions, and important unanswered questions in advanced drug delivery.

SpheroFill Insights official podcast cover artwork
FEATURED INTRODUCTORY EPISODE

Tiny Bubbles, Big Possibilities

Meet the porous-wall hollow glass microsphere. Discover the origin of the platform, how its architecture works, and why a tiny glass reservoir might offer new opportunities for pharmaceutical delivery.

COMMON QUESTIONS

A closer look

Are these the same as conventional mesoporous silica particles?

No. Both involve silica-rich materials, but the PWHGM architecture has a substantial hollow reservoir connected to the exterior through a porous wall. This creates a different relationship between the cargo compartment and the porous transport pathways.

How large are the microspheres?

Particles used in SpheroFill's current work commonly fall in the 20–40 micrometer diameter range. Size distributions and release specifications are confirmed by batch.

Has oral delivery efficacy been established?

Not yet. Oral bioavailability, targeting performance, and clinical benefit require indication- and formulation-specific preclinical and clinical evidence. The website describes research opportunities, not an approved oral drug product.

Are applications limited to oral delivery?

No. The platform's broader research history includes local delivery and regenerative medicine concepts. Oral delivery is a current development emphasis rather than an intrinsic limitation of the technology.

LET'S EXPLORE WHAT'S POSSIBLE

Have a challenging formulation problem?

We welcome scientific conversations about where a hollow-reservoir delivery platform could provide a useful new approach.

Start a conversation ↗